What is the recommended dosing of brivaracetam?

Brivaracetam Dosing

The recommended starting dose of brivaracetam is 50 mg twice daily (100 mg/day total), which can be initiated without titration and adjusted to 25-100 mg twice daily based on clinical response and tolerability. 1

Standard Adult Dosing

• Initial dose: 50 mg twice daily (100 mg/day total) without requiring titration 1
• Dose range: 25-100 mg twice daily (50-200 mg/day total) 1, 2
• Maximum recommended dose: 100 mg twice daily (200 mg/day total) 1
• Brivaracetam can be administered with or without food, though high-fat meals delay absorption by 3 hours without significantly affecting total exposure 1

Pediatric Dosing (1 month to <16 years)

Weight-based dosing is required for pediatric patients to achieve exposures similar to adults: 1

• Dosing regimen: 2.0 mg/kg twice daily 3
• Maximum dose: 100 mg twice daily for patients weighing >50 kg 1, 3
• Plasma concentrations are dose-proportional in pediatric patients aged 2 months to <16 years 1
• Estimated plasma clearance varies by weight: 1.09 L/h (11 kg), 1.81 L/h (20 kg), and 3.11 L/h (50 kg) compared to 3.58 L/h in adults 1

Dose Adjustments for Special Populations

Hepatic Impairment

Dose reduction is required for all stages of hepatic impairment: 1

• Starting dose: 25 mg twice daily (50 mg/day) for all stages (Child-Pugh A, B, and C) 1
• Maximum dose: 75 mg twice daily (150 mg/day) 1
• Brivaracetam exposure increases by 50%, 57%, and 59% in Child-Pugh grades A, B, and C, respectively 1

Renal Impairment

• No dose adjustment required for any degree of renal impairment, including severe renal dysfunction (CrCl <30 mL/min) 1
• Brivaracetam plasma AUC increases only 21% in severe renal impairment 1
• Less than 10% of the dose is excreted unchanged in urine, making hemodialysis unlikely to enhance clearance 1

Elderly Patients (≥65 years)

• No dose adjustment required based on age alone 1
• Plasma clearance is slightly lower (0.76 mL/min/kg) compared to young adults (0.83 mL/min/kg) 1

Drug Interactions Affecting Dosing

CYP2C19 Poor Metabolizers

Consider dose reduction in CYP2C19 poor metabolizers or patients taking strong CYP2C19 inhibitors: 1

• Brivaracetam levels increase by 22% in heterozygous carriers and 42% in homozygous poor metabolizers 1
• The hydroxy metabolite production decreases 2-fold or 10-fold depending on genetic variation 1

Concomitant Enzyme-Inducing Antiepileptic Drugs

No dose adjustment is required when brivaracetam is used with carbamazepine or phenytoin, though these drugs reduce brivaracetam exposure: 1

• Carbamazepine decreases brivaracetam exposure by approximately 26-32% 1, 3
• Phenobarbital decreases brivaracetam exposure by approximately 29% 3
• Despite reduced exposure, efficacy is maintained without dose adjustment 3

Formulation Equivalence

All three formulations (tablets, oral solution, injection) can be used interchangeably without dose adjustment: 1

• Tablets: 10,25,50,75, and 100 mg strengths 1
• Oral solution: 10 mg/mL 1
• Intravenous injection: 10 mg/mL (50 mg per 5 mL vial) administered over 2-15 minutes 1

Clinical Efficacy by Dose

Phase 3 trials demonstrated efficacy primarily at 100-200 mg/day, with some studies showing benefit at 50 mg/day: 4

• The 50 mg twice daily dose showed responder rates of 47% and 45% in monotherapy conversion studies 5
• Higher doses (100-200 mg/day) consistently demonstrated superior efficacy in adjunctive therapy trials 4

Common Pitfalls

• Avoid unnecessary titration: Unlike many antiepileptic drugs, brivaracetam does not require gradual dose escalation 1
• Remember hepatic dose reduction: This is the only population requiring mandatory dose adjustment 1
• Do not adjust for renal impairment: Despite significant increases in inactive metabolites, brivaracetam itself requires no dose modification 1